Durham, NC, United States
Durham, NC, United States

Time filter

Source Type

News Article | November 3, 2016
Site: marketersmedia.com

— Huge R&D investments in bio-tech companies to develop applications in the field of diagnostics is the major factor propelling the market growth. In addition, high cost efficiency of aptamers, and technological developments are the key factors driving the market growth. However, strict regulations, ethical issues related to using aptamers, and lack of trained professional are the factors inhibiting the market growth. Nucleic acid aptamers segment is witnessing a significant growth driven by increasing research and development activities and growing usage in diagnostic applications for the treatment of diseases such as autoimmune diseases, cancer and HIV/AIDS. North America is anticipated to be the largest market for aptamers, whereas Asia Pacific is projected to grow at a faster pace. Favorable government initiatives and increased research and development activities in the U.S are propelling the market growth in North America region. Some of the key players in global aptamers market include Bioapter S.L., Base Pair Biotechnologies, Inc., Optech Biotech, Ophthotech Corporation, NOXXON Pharma AG, Neoventures Biotechnology Inc., CD Genomics, Aptagen, LLC, Am Biotechnologies, LLC, Aptus Biotech S.L., Aptamer Solutions Ltd., Aptamer Sciences Inc., Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., and Regado Biosciences, Inc. Applications Covered: • Diagnostics o Biomarker Detection and Discovery o Molecular Imaging • Therapeutics Development • Research and Development o Drug Discovery and Development o Targeted Drug Delivery • Other Applications o Biosensor o Food Safety Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


Patent
Regado Biosciences | Date: 2014-10-07

The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.


Patent
Regado Biosciences | Date: 2013-12-06

The present invention relates generally to pharmaceutical formulations of conjugated oligonucleotides, such as pegylated aptamers, as well as to a method of preparing and using the same. The pharmaceutical formulations have desirable shelf life characteristics under varied storage conditions. Formulations of oligonucleotides or oligonucleotides conjugates and methods for their preparation and use are provided having a shelf life of at least about 24 months or, more preferably, at least about 36 months at about 2 to about 30 C. In particular embodiments, the formulations have a pH of about 7 or less and contain methionine. Optionally, dissolved oxygen content is reduced during the manufacturing process is used to improve desired shelf life characteristics.


Patent
Regado Biosciences | Date: 2014-11-13

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.


Patent
Regado Biosciences | Date: 2012-06-06

The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.


Patent
Regado Biosciences | Date: 2010-06-03

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.


Patent
Regado Biosciences | Date: 2012-11-07

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.


Patent
Regado Biosciences | Date: 2012-11-07

The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.


Patent
Regado Biosciences | Date: 2010-04-12

The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.


Patent
Regado Biosciences | Date: 2013-01-28

The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.

Loading Regado Biosciences collaborators
Loading Regado Biosciences collaborators